Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: CNBC World

What happened

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Key facts

  • Reported by CNBC World and published Fri, 02 Oct 2026 17:55:26 UTC.

Why it matters

International stories like this one shape diplomacy, travel, energy supply and security decisions well beyond the country involved, which is why WorldPing tracks every update on it in one place.

What to watch next

  • Official statements or denials from the governments named
  • Whether other major newsrooms confirm the same details
  • Any follow-up decision, vote or deadline tied to the event

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

  2. G7 to release 100 million barrels of oil and diesel after Trump export ban threat

  3. Iraq grants Iranian airlines 40 daily Najaf flights after US exemption

  4. US murderer Christa Pike unconscious and on ventilator after failed execution, lawyers say

  5. Cases clubbed only after CJI spoke to presiding judges

  6. Christa Pike unconscious, on ventilator after botched execution: Lawyers

  7. France held 1-1 by Italy in Zidane home debut after Olise stunner

Sources

The original report was published by CNBC World. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at CNBC World

Related WorldPing coverage